Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma.
|
11238734 |
2001 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of MET in GBM mouse models blocks mesenchymal transition and invasion provoked by VEGF ablation, resulting in substantial survival benefit.
|
22789536 |
2012 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast to the classical subtype of primary glioblastoma, the cases studied here were characterized by the absence of EGFR amplification, PTEN loss, and 9p homozygous deletion and overexpression of p53, PDGFRα, and c-MET, suggesting that they can be classified as the proneural or mesenchymal subtype of glioblastoma and benefit from intensive therapy that includes temozolomide.
|
24457079 |
2014 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recurrence of GB after chemo-radiation could be associated with a variation in PlGF and MET expression.
|
27566180 |
2016 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, TBMS1 is a promising compound for the treatment of glioblastoma and an inhibitor of MET.
|
31349699 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our studies reveal a novel mechanism to alter the recycling process of MET in glioblastoma cancer cells by promoting the receptor degradation through a proteasome-sensitive and lysosome-dependent pathway through the ligand-independent activation of MET using anti-MET antibodies.
|
30760737 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
|
27748748 |
2016 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the effect of HGF/SF on matrix metalloproteinase-2 (MMP-2), membrane type 1 matrix metalloproteinase (MT1-MMP) and tissue inhibitors of metalloproteinases (TIMPs), expressions of c-Met/HGF receptor-positive human glioblastoma cells.
|
10389763 |
1999 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that expression of the MET oncogene was associated with neurospheres expressing the gene signature of mesenchymal and proneural subtypes of glioblastoma.
|
22738909 |
2012 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting Dock7 in GBM may inhibit c-MET-mediated invasion in tumours treated with anti-angiogenic regimens.
|
24518591 |
2014 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previously, it was demonstrated that treatment with cabozantinib (MET/VEGFR2/RET inhibitor) prolonged survival of mice carrying orthotopic patient-derived xenografts (PDX) of the MET-addicted glioblastoma model E98, yet did not prevent development of recurrent and cabozantinib-resistant tumors.
|
28751462 |
2017 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tf-NP-miR-1 treatment on GBM spheres significantly inhibited migration of GBM spheres by 30-50% with associated decline of MET and EGFR expression.
|
25374033 |
2014 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amplified met gene linked to double minutes in human glioblastoma.
|
8280494 |
1993 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, combined treatment with BH3-mimetics and c-MET inhibitors results in significantly smaller tumors than each treatment alone in a PDX model system of glioblastoma.
|
29743557 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
The oncogene MET was amplified in a glioblastoma which showed no EGFR gene amplification.
|
8017863 |
1994 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We show that the RTKs MET, EGFR, and PDGFR regulate microRNA-134 (miR-134) in GBM.
|
24440911 |
2014 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
|
26381735 |
2015 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data provide new insights into the potential application of miR-144-3p in GBM therapy by targeting MET and then inhibiting the downstream signaling.
|
26250785 |
2015 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of the five target genes that were enriched in the glioblastoma pathway, in the WikiPathway database, both HRas proto-oncogene, GTPase and MET proto-oncogene, receptor tyrosine kinase target genes of hsa-miR-139-5p, were found to be significantly associated with patient survival.
|
31423264 |
2019 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we identify a distinct fraction of cells in a genetically engineered mouse model of EGFR-driven GBM that respond to anti-EGFR therapy by inducing high levels of c-MET expression.
|
24115218 |
2014 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GBM tissues frequently overexpressed MET protein at high levels compared with lower-grade gliomas.
|
28668888 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We could also localize the MET amplicon to dmins in glioblastoma TX3095 by fluorescence in situ hybridization.
|
7534113 |
1995 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme.
|
22020333 |
2012 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we review findings that associate MET expression and activity with a specific, genetically defined glioblastoma stem cell subtype, and data showing how MET sustains the stem cell phenotype in glioblastoma and other tumors.
|
23695554 |
2013 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In cells and tumors that express EGFRvIII, SHP2 also antagonizes the phosphorylation of EGFRvIII and c-MET and drives expression of HIF-1α and HIF-2α, adding complexity to the evolving understanding of the regulatory functions of SHP2 in GBM.
|
24951116 |
2014 |